Monopar Therapeutics Inc.
MNPR
$77.19
$1.251.64%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -163.56% | -43.04% | -59.94% | -502.33% | 33.24% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 452.08% | 282.63% | 312.23% | 918.75% | -58.00% |
| Change in Net Operating Assets | 682.02% | 132.65% | -1,181.25% | 2,086.57% | 106.89% |
| Cash from Operations | -94.74% | 35.75% | -242.11% | -29.27% | 44.66% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -315.68% | 49,570.83% | 66.87% | -582.71% | 7,624.43% |
| Cash from Investing | -315.68% | 49,570.83% | 66.87% | -582.71% | 7,624.43% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 4,600.00% | -99.52% | 16,435.39% | -100.00% |
| Repurchase of Common Stock | -214,333.33% | -3,116.00% | -1,125.23% | -1,162.26% | -101.22% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 560,049.09% | -3,100.00% | -103.64% | 16,682.30% | -106.69% |
| Foreign Exchange rate Adjustments | -91.11% | -273.33% | 94.12% | 54.76% | -33.82% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 88,452.10% | 87.59% | -1,227.41% | 2,173.16% | 94.13% |